Amendment: SEC Form SC 13G/A filed by Biogen Inc.

11/4/24 11:20:12 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BIIB alert in real time by email

SC 13G/A 1 UnitedStates_13G__BiogenIncU.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* (Name of Issuer) Biogen Inc (Title of Class of Securities) Common Stock (CUSIP Number) 09062X103 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 09062X103 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 179,337 (7) Sole dispositive power 16,033,598 (8) Shared dispositive power 644,208 (9) Aggregate amount beneficially owned by each reporting person 16,677,806 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 11.44% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Biogen Inc Item 1(b) Address of issuer's principal executive offices: 225 Binney Street Cambridge, MA 02142 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 09062X103 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 16,677,806 (b) Percent of class: 11.44% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 16,677,806 (b) Percent of class: 11.44% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 179,337 (iii) Sole power to dispose or to direct the disposition of: 16,033,598 (iv) Shared power to dispose or to direct the disposition of: 644,208 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by th

Get the next $BIIB alert in real time by email

Recent Analyst Ratings for

$BIIB

Date	Price Target	Rating	Analyst
9/25/2025	$190.00	Buy	Jefferies
7/21/2025	$142.00	Hold	Truist
4/28/2025	$118.00	Buy → Hold	HSBC Securities
4/4/2025		Buy → Hold	Argus
2/11/2025	$160.00	Mkt Perform	Bernstein
1/2/2025	$315.00 → $138.00	Overweight → Neutral	Piper Sandler
12/20/2024	$230.00 → $164.00	Outperform → Market Perform	BMO Capital Markets
12/16/2024	$175.00	Buy → Hold	Stifel

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Biogen Inc.

11/4/24 11:20:12 AM ET

$BIIB

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BIIB alert in real time by email

Recent Analyst Ratings for

$BIIB

Date	Price Target	Rating	Analyst
9/25/2025	$190.00	Buy	Jefferies
7/21/2025	$142.00	Hold	Truist
4/28/2025	$118.00	Buy → Hold	HSBC Securities
4/4/2025		Buy → Hold	Argus
2/11/2025	$160.00	Mkt Perform	Bernstein
1/2/2025	$315.00 → $138.00	Overweight → Neutral	Piper Sandler
12/20/2024	$230.00 → $164.00	Outperform → Market Perform	BMO Capital Markets
12/16/2024	$175.00	Buy → Hold	Stifel

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Biogen Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $BIIB

Amendment: SEC Form SC 13G/A filed by Biogen Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $BIIB

$BIIB Insider Purchases

Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

$BIIB FDA approvals

FDA Approval for VUMERITY issued to BIOGEN INC

FDA Approval for VUMERITY issued to BIOGEN INC

FDA Approval for VUMERITY issued to BIOGEN INC

$BIIB SEC Filings

Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Biogen Inc.

Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$BIIB Analyst Ratings

Jefferies initiated coverage on Biogen with a new price target

Truist resumed coverage on Biogen with a new price target

Biogen downgraded by HSBC Securities with a new price target

$BIIB Press Releases

/C O R R E C T I O N -- National Association of Corporate Directors/

Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

$BIIB Insider Trading

Chief Accounting Officer Godbout Sean converted options into 26 shares and covered exercise/tax liability with 8 shares, increasing direct ownership by 4% to 495 units (SEC Form 4)

Head of Development Singhal Priya converted options into 1,669 shares, covered exercise/tax liability with 807 shares and sold $69,045 worth of shares (517 units at $133.55), increasing direct ownership by 6% to 5,772 units (SEC Form 4)

Head of Global Product Strat. Izzar Rachid sold $300,105 worth of shares (2,223 units at $135.00), decreasing direct ownership by 26% to 6,330 units (SEC Form 4)

$BIIB Financials

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

$BIIB Large Ownership Changes